Chengdu Kanghong Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceuticals and medical devices in China. It develops medicines for ophthalmic and neuropsychiatric uses, among others. The company was founded in 1996 and is headquartered in Chengdu, China.
Kanghong Pharmaceutical's 2026 interim net profit was 565 million yuan, down 22.61% year on year
Kanghong Pharmaceutical released its 2026 interim report. Total operating revenue was 2.179 billion yuan, down 11.19% from the same period last year. Net profit attributable to the parent company was 565 million yuan, down 22.61% year on year. Net cash inflow from operating activities was 540 million yuan, down 41.06% year on year. The company's latest asset-liability ratio was 7.63%, gross margin was 88.50%, ROE was 6.13%, and diluted earnings per share was 0.61 yuan, down 22.78% year on year. The number of shareholders was 37,900, and the top ten shareholders held 72.84% of the total share capital.
Kanghong Pharmaceutical's first-half net profit attributable to parent falls 22.6% to 565 million yuan
Kanghong Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 565 million yuan, down 22.6% year on year. Operating revenue was 2.18 billion yuan, down 11.2% year on year. Net profit attributable to the parent after deducting non-recurring items was 557 million yuan, down 22.9% year on year. Net operating cash flow was 540 million yuan, down 41.1% year on year. Second-quarter operating revenue was 1.13 billion yuan, down 9.7% year on year, and net profit attributable to the parent was 257 million yuan, down 22.0% year on year. As of the end of the second quarter, total assets were 9.939 billion yuan, up 0.2% from the end of the previous year, and net assets attributable to the parent were 9.215 billion yuan, down 0.9% from the end of the previous year.
Kanghong Pharmaceutical's Perampanel Tablets Proposed for Selection in the 12th National Drug Procurement
Kanghong Pharmaceutical announced that its product Perampanel Tablets has been proposed for selection in the 12th round of national centralized drug procurement. The drug is indicated for the treatment of partial-onset seizures in adults and children aged 4 years and older.
Kanghong Pharmaceutical announced that its subsidiary, Chengdu Hongji Biotechnology, has recently received a drug clinical trial approval notice issued by the National Medical Products Administration for its KHN921 injection. The indication is for the treatment of hypertrophic cardiomyopathy caused by MYBPC3 mutations. This product is an AAV gene therapy independently developed by Hongji Biotechnology, and it had previously received clearance from the U.S. FDA to conduct clinical trials in April 2026. KHN921 injection uses a novel adeno-associated virus with the company's proprietary intellectual property as a vector, precisely targeting myocardial tissue. By delivering functional target genes, it corrects the pathogenic mutation at the genetic level, aiming to improve myocardial structure and function, and delay or reverse disease progression.
Four Kanghong Pharma Products Newly Added to National Essential Medicines List
Kanghong Pharmaceutical announced that 13 major products sold by the company and its subsidiaries have been included in the National Essential Medicines List, 2026 Edition. Among them, Conbercept Ophthalmic Injection Prefilled Syringe, Shugan Jieyu Capsules, Eszopiclone Tablets, and Tofacitinib Citrate Extended-Release Tablets are the four newly added products. The new list takes effect on September 1, 2026. The inclusion will facilitate the promotion and use of the products in medical institutions at all levels, and is expected to have a positive impact on market expansion and long-term development. In the first quarter of 2026, Kanghong Pharmaceutical achieved revenue of 1.046 billion yuan and net profit attributable to the parent company of 307 million yuan.
Kanghong Pharma's 13 Products Included in the 2026 National Essential Medicines List
Kanghong Pharma announced that a total of 13 key products from the company and its subsidiaries have been included in the National Essential Medicines List, 2026 edition. Among them, four are newly added products: Conbercept Ophthalmic Injection prefilled syringe, Shugan Jieyu Capsules, Eszopiclone Tablets, and Tofacitinib Citrate Extended-Release Tablets. The new list takes effect on September 1, 2026, which will facilitate the promotion and use of these products in medical institutions at all levels, but the impact on current operating performance cannot be accurately estimated at this time.
China